{"slug":"immunotherapy","tag":"immunotherapy","variants":["immunotherapy"],"description":"People whose work centres on immunotherapy.","count":76,"kinds":{"person":76},"related":[{"slug":"trialist","tag":"trialist","shared":23},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":15},{"slug":"leadership","tag":"leadership","shared":13},{"slug":"melanoma","tag":"melanoma","shared":9},{"slug":"skin","tag":"skin","shared":6},{"slug":"head-and-neck","tag":"head-and-neck","shared":5},{"slug":"lung","tag":"lung","shared":5},{"slug":"adjuvant","tag":"adjuvant","shared":4},{"slug":"mesothelioma","tag":"mesothelioma","shared":4},{"slug":"surgery","tag":"surgery","shared":4},{"slug":"urothelial","tag":"urothelial","shared":4},{"slug":"endometrial","tag":"endometrial","shared":3}],"records":[{"id":"sandra-demaria","kind":"person","name":"Sandra Demaria","route":"/people/sandra-demaria/","tldr":"Weill Cornell pathologist-immunologist known for radiation-immunotherapy research; SITC Vice President."},{"id":"dirk-schadendorf","kind":"person","name":"Dirk Schadendorf","route":"/people/dirk-schadendorf/","tldr":"Melanoma expert who directs the West German Cancer Center at University Hospital Essen."},{"id":"adrian-ochsenbein","kind":"person","name":"Adrian Ochsenbein","route":"/people/adrian-ochsenbein/","tldr":"Bern medical oncology chief whose lab targets leukaemia stem cells and CD70 signalling."},{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","route":"/people/luis-paz-ares/","tldr":"Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer."},{"id":"jurgen-kuball","kind":"person","name":"Jürgen Kuball","route":"/people/jurgen-kuball/","tldr":"Utrecht haematologist and immunotherapy researcher on the daily board of UMC Utrecht's cancer programme, known for gamma-delta T cell receptor-engineered cell therapies."},{"id":"kunle-odunsi","kind":"person","name":"Kunle Odunsi","route":"/people/kunle-odunsi/","tldr":"Gynaecologic oncologist and immunotherapy researcher who directs the University of Chicago Medicine Comprehensive Cancer Center."},{"id":"ralph-weichselbaum","kind":"person","name":"Ralph Weichselbaum","route":"/people/ralph-weichselbaum/","tldr":"Radiation oncologist at the University of Chicago known for the oligometastasis concept and for research linking radiation with anti-tumour immunity."},{"id":"peter-johnson","kind":"person","name":"Peter Johnson","route":"/people/peter-johnson/","tldr":"Southampton lymphoma specialist who led the RATHL trial of PET-guided therapy in Hodgkin lymphoma and serves as NHS England's National Clinical Director for Cancer."},{"id":"bruno-sangro","kind":"person","name":"Bruno Sangro","route":"/people/bruno-sangro/","tldr":"Hepatologist at Clínica Universidad de Navarra and a leading international investigator in liver cancer systemic therapy and radioembolisation."},{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","route":"/people/alfredo-addeo/","tldr":"Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals."},{"id":"karim-vermaelen","kind":"person","name":"Karim Vermaelen","route":"/people/karim-vermaelen/","tldr":"Thoracic oncologist and tumour immunologist who chairs the Cancer Research Institute Ghent at Ghent University / UZ Gent."},{"id":"antonio-rosato","kind":"person","name":"Antonio Rosato","route":"/people/antonio-rosato/","tldr":"Immunologist and Scientific Director of the Istituto Oncologico Veneto, leading its translational cancer research."},{"id":"rebecca-auer","kind":"person","name":"Rebecca Auer","route":"/people/rebecca-auer/","tldr":"Cancer surgeon and scientist who leads research and innovation at The Ottawa Hospital and its research institute."},{"id":"john-stagg","kind":"person","name":"John Stagg","route":"/people/john-stagg/","tldr":"Immunologist who studies why tumours resist immunotherapy and directs the Goodman Cancer Institute, McGill University's cancer research institute in Montreal."},{"id":"marco-herold","kind":"person","name":"Marco Herold","route":"/people/marco-herold/","tldr":"Cancer biologist who leads the Olivia Newton-John Cancer Research Institute, the research arm of the Olivia Newton-John Cancer Wellness and Research Centre in Melbourne."},{"id":"peter-schmid","kind":"person","name":"Peter Schmid","route":"/people/peter-schmid/","tldr":"Led KEYNOTE-522 and IMpassion130, the trials that brought immunotherapy into triple-negative breast cancer."},{"id":"elizabeth-mittendorf","kind":"person","name":"Elizabeth A. Mittendorf","route":"/people/elizabeth-mittendorf/","tldr":"Surgeon-scientist who led IMpassion031 and studies of surgery de-escalation after neoadjuvant immunotherapy."},{"id":"roy-herbst","kind":"person","name":"Roy S. Herbst","route":"/people/roy-herbst/","tldr":"Lung cancer trialist behind KEYNOTE-010 and the ADAURA adjuvant osimertinib trial."},{"id":"martin-reck","kind":"person","name":"Martin Reck","route":"/people/martin-reck/","tldr":"Led KEYNOTE-024, the trial that made pembrolizumab alone first-line therapy for PD-L1-high lung cancer."},{"id":"scott-antonia","kind":"person","name":"Scott J. Antonia","route":"/people/scott-antonia/","tldr":"Led PACIFIC, which made a year of durvalumab after chemoradiation the standard for stage III lung cancer."},{"id":"tina-cascone","kind":"person","name":"Tina Cascone","route":"/people/tina-cascone/","tldr":"Led CheckMate 77T, one of the perioperative immunotherapy trials that changed how operable lung cancer is treated."},{"id":"thierry-andre","kind":"person","name":"Thierry André","route":"/people/thierry-andre/","tldr":"Led MOSAIC, which made FOLFOX the adjuvant standard, and KEYNOTE-177, which made pembrolizumab first-line for MSI-high colon cancer."},{"id":"heinz-josef-lenz","kind":"person","name":"Heinz-Josef Lenz","route":"/people/heinz-josef-lenz/","tldr":"Colorectal oncologist who led CheckMate 142 and co-led CheckMate 8HW, bringing nivolumab plus ipilimumab to MSI-high disease."},{"id":"vinod-balachandran","kind":"person","name":"Vinod P. Balachandran","route":"/people/vinod-balachandran/","tldr":"Surgeon-scientist whose personalised mRNA vaccine trial showed pancreatic cancer can provoke lasting T-cell immunity."},{"id":"jaffer-ajani","kind":"person","name":"Jaffer A. Ajani","route":"/people/jaffer-ajani/","tldr":"Gastro-oesophageal oncologist who co-led CheckMate 649, the trial that added nivolumab to first-line gastric cancer chemotherapy."},{"id":"ronan-kelly","kind":"person","name":"Ronan J. Kelly","route":"/people/ronan-kelly/","tldr":"Led CheckMate 577, the first trial to show adjuvant immunotherapy helps oesophageal cancer patients with residual disease."},{"id":"ken-kato","kind":"person","name":"Ken Kato","route":"/people/ken-kato/","tldr":"Japanese oncologist who led ATTRACTION-3 and KEYNOTE-590, bringing immunotherapy to oesophageal cancer."},{"id":"ann-lii-cheng","kind":"person","name":"Ann-Lii Cheng","route":"/people/ann-lii-cheng/","tldr":"Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer."},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","tldr":"Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer."},{"id":"dean-bajorin","kind":"person","name":"Dean F. Bajorin","route":"/people/dean-bajorin/","tldr":"Led CheckMate 274, which established adjuvant nivolumab after bladder cancer surgery."},{"id":"joaquim-bellmunt","kind":"person","name":"Joaquim Bellmunt","route":"/people/joaquim-bellmunt/","tldr":"Led KEYNOTE-045, the first trial to show immunotherapy beats chemotherapy in advanced bladder cancer."},{"id":"arjun-balar","kind":"person","name":"Arjun V. Balar","route":"/people/arjun-balar/","tldr":"Led KEYNOTE-052 and IMvigor210 cohort 1, establishing first-line immunotherapy for cisplatin-ineligible bladder cancer."},{"id":"brian-rini","kind":"person","name":"Brian I. Rini","route":"/people/brian-rini/","tldr":"Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer."},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","tldr":"Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease."},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/","tldr":"Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer."},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/","tldr":"Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer."},{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","route":"/people/jedd-wolchok/","tldr":"Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive."},{"id":"caroline-robert","kind":"person","name":"Caroline Robert","route":"/people/caroline-robert/","tldr":"Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma."},{"id":"paolo-ascierto","kind":"person","name":"Paolo A. Ascierto","route":"/people/paolo-ascierto/","tldr":"Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial."},{"id":"michael-postow","kind":"person","name":"Michael A. Postow","route":"/people/michael-postow/","tldr":"Led CheckMate 069, the first randomised trial of nivolumab plus ipilimumab, and defines how to manage immunotherapy side effects."},{"id":"timothy-cloughesy","kind":"person","name":"Timothy F. Cloughesy","route":"/people/timothy-cloughesy/","tldr":"Neuro-oncologist whose neoadjuvant PD-1 trial showed immunotherapy before surgery can activate immune responses in glioblastoma."},{"id":"barbara-burtness","kind":"person","name":"Barbara Burtness","route":"/people/barbara-burtness/","tldr":"Led KEYNOTE-048, which made pembrolizumab first-line therapy for recurrent or metastatic head and neck cancer."},{"id":"ezra-cohen","kind":"person","name":"Ezra E. W. Cohen","route":"/people/ezra-cohen/","tldr":"Led KEYNOTE-040, which showed pembrolizumab improves survival in previously treated head and neck cancer."},{"id":"paul-baas","kind":"person","name":"Paul Baas","route":"/people/paul-baas/","tldr":"Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years."},{"id":"dean-fennell","kind":"person","name":"Dean A. Fennell","route":"/people/dean-fennell/","tldr":"Led CONFIRM and MARS 2, which showed nivolumab helps relapsed mesothelioma and that radical surgery does not."},{"id":"anna-nowak","kind":"person","name":"Anna K. Nowak","route":"/people/anna-nowak/","tldr":"Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma."},{"id":"nai-kong-cheung","kind":"person","name":"Nai-Kong V. Cheung","route":"/people/nai-kong-cheung/","tldr":"Developed the anti-GD2 antibodies 3F8 and naxitamab that treat relapsed neuroblastoma."},{"id":"sumit-gupta","kind":"person","name":"Sumit Gupta","route":"/people/sumit-gupta/","tldr":"Led COG AALL1731, which showed adding blinatumomab to chemotherapy improves survival for children with standard-risk leukaemia."},{"id":"elias-jabbour","kind":"person","name":"Elias Jabbour","route":"/people/elias-jabbour/","tldr":"Leukaemia specialist who built chemotherapy-light regimens combining inotuzumab, blinatumomab and ponatinib for adult ALL."},{"id":"lieping-chen","kind":"person","name":"Lieping Chen","route":"/people/lieping-chen/","tldr":"Discovered PD-L1 (B7-H1) and showed tumours use it to escape immunity, the biology behind every anti-PD-1 drug."},{"id":"gordon-freeman","kind":"person","name":"Gordon J. Freeman","route":"/people/gordon-freeman/","tldr":"Showed that PD-L1 is the ligand for PD-1 and that the pair switches T cells off, the foundation of checkpoint immunotherapy."},{"id":"thomas-gajewski","kind":"person","name":"Thomas F. Gajewski","route":"/people/thomas-gajewski/","tldr":"Defined the T-cell-inflamed tumour, discovered STING's role in anti-tumour immunity and showed gut bacteria shape immunotherapy response."},{"id":"ugur-sahin","kind":"person","name":"Uğur Şahin","route":"/people/ugur-sahin/","tldr":"Immunologist who built individualised mRNA neoantigen vaccines for cancer, the platform later used for COVID-19."},{"id":"howard-kaufman","kind":"person","name":"Howard L. Kaufman","route":"/people/howard-kaufman/","tldr":"Led OPTiM, the trial that made talimogene laherparepvec the first approved oncolytic virus therapy."},{"id":"ignacio-melero","kind":"person","name":"Ignacio Melero","route":"/people/ignacio-melero/","tldr":"Spanish immunologist who pioneered CD137 agonist antibodies and intratumoural immunotherapy."},{"id":"matthew-hellmann","kind":"person","name":"Matthew D. Hellmann","route":"/people/matthew-hellmann/","tldr":"Lung cancer doctor who was the lead author of CheckMate 227, the trial that showed the immunotherapy pair nivolumab and ipilimumab helps people with advanced lung cancer live longer than chemotherapy alone."},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","tldr":"Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer."},{"id":"robin-kate-kelley","kind":"person","name":"Robin Kate Kelley","route":"/people/robin-kate-kelley/","tldr":"San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer."},{"id":"philippe-armand","kind":"person","name":"Philippe Armand","route":"/people/philippe-armand/","tldr":"Boston lymphoma doctor who led KEYNOTE-170, the trial that showed pembrolizumab can control relapsed primary mediastinal B-cell lymphoma, and who helped bring PD-1 blockade to Hodgkin lymphoma."},{"id":"michael-atkins","kind":"person","name":"Michael B. Atkins","route":"/people/michael-atkins/","tldr":"Washington oncologist who led DREAMseq, the trial that showed people with BRAF-mutant melanoma live longer if immunotherapy is given before targeted therapy rather than after."},{"id":"alexander-stratigos","kind":"person","name":"Alexander J. Stratigos","route":"/people/alexander-stratigos/","tldr":"Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines."},{"id":"michael-migden","kind":"person","name":"Michael R. Migden","route":"/people/michael-migden/","tldr":"Houston dermatologist who led the trials that established cemiplimab, the first drug approved for advanced cutaneous squamous-cell carcinoma, and sonidegib for basal cell carcinoma."},{"id":"jean-jacques-grob","kind":"person","name":"Jean-Jacques Grob","route":"/people/jean-jacques-grob/","tldr":"Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials."},{"id":"danny-rischin","kind":"person","name":"Danny Rischin","route":"/people/danny-rischin/","tldr":"Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma."},{"id":"neil-gross","kind":"person","name":"Neil D. Gross","route":"/people/neil-gross/","tldr":"Houston surgeon who led the trial showing that giving cemiplimab before surgery can eliminate cutaneous squamous-cell carcinoma in about half of patients, sparing many from extensive operations."},{"id":"ralf-gutzmer","kind":"person","name":"Ralf Gutzmer","route":"/people/ralf-gutzmer/","tldr":"German dermato-oncologist who was lead author of IMspire150, the trial that added atezolizumab to vemurafenib and cobimetinib in BRAF-mutant melanoma."},{"id":"shailender-bhatia","kind":"person","name":"Shailender Bhatia","route":"/people/shailender-bhatia/","tldr":"Seattle oncologist who led STAMP, the trial that showed pembrolizumab after surgery reduces recurrence of Merkel cell carcinoma, a rare and aggressive skin cancer."},{"id":"robert-ferris","kind":"person","name":"Robert L. Ferris","route":"/people/robert-ferris/","tldr":"Surgeon and immunologist who led CheckMate 141, the trial that made nivolumab the first drug to lengthen survival in head and neck cancer after platinum failure, and E3311 on transoral surgery for HPV-positive throat cancer."},{"id":"jean-pascal-machiels","kind":"person","name":"Jean-Pascal Machiels","route":"/people/jean-pascal-machiels/","tldr":"Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer."},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","tldr":"New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy."},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","tldr":"Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers."},{"id":"inge-van-der-sluis","kind":"person","name":"Inge M. van der Sluis","route":"/people/inge-van-der-sluis/","tldr":"Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia."},{"id":"alice-chen","kind":"person","name":"Alice P. Chen","route":"/people/alice-chen/","tldr":"NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer."},{"id":"quincy-chu","kind":"person","name":"Quincy Chu","route":"/people/quincy-chu/","tldr":"Edmonton oncologist who was lead author of KEYNOTE-483 (CCTG IND.227), the trial that showed adding pembrolizumab to chemotherapy lengthens survival in pleural mesothelioma."},{"id":"jeffrey-bluestone","kind":"person","name":"Jeffrey A. Bluestone","route":"/people/jeffrey-bluestone/","tldr":"The immunologist who ran the Parker Institute from its launch in 2016, building a shared research network across leading US cancer centres; he came from UCSF and now leads a regulatory T cell company."},{"id":"karen-knudsen","kind":"person","name":"Karen E. Knudsen","route":"/people/karen-knudsen/","tldr":"The cancer biologist and former American Cancer Society chief executive who now runs the Parker Institute for Cancer Immunotherapy."}]}